Indrayani Biotech responds to BSE query on share price movement citing full regulatory compliance.
Attributes price action to disclosed rights issue committee and demerger proposal board meetings.
Confirms no undisclosed material information exists beyond recent statutory intimations.
Company states price movement is market-driven and reaffirms commitment to listing regulations.